Aktis Oncology (NASDAQ:AKTS) Receives $31.25 Consensus Price Target from Analysts

Aktis Oncology (NASDAQ:AKTS) has earned a consensus recommendation of “Buy” from the five research firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have covered the stock in the last year is $31.25.

A number of research firms recently issued reports on AKTS. HC Wainwright started coverage on Aktis Oncology in a research note on Monday. They set a “buy” rating and a $30.00 price objective on the stock. Bank of America initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price for the company. JPMorgan Chase & Co. assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price target on the stock. Leerink Partners initiated coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 price target on the stock. Finally, Wall Street Zen raised shares of Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th.

Trending Headlines about Aktis Oncology

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and set a $30 price target, which can act as a near-term bullish catalyst by drawing buy-side interest and framing upside vs. the current share price. HC Wainwright Note
• Neutral Sentiment: Recent short-interest reports show “0 shares” and a days-to-cover of 0.0 — this appears to be a reporting anomaly (NaN/inconsistent increases noted) and is not actionable until corrected data is posted. Short Interest Report
• Negative Sentiment: HC Wainwright’s published EPS forecasts project continued and widening losses over the next several years (examples: FY2025 EPS ≈ ($2.39); FY2026 ≈ ($2.95); FY2027 ≈ ($3.71); quarterly FY2026 losses also projected). Those loss projections highlight ongoing cash-burn and execution risk that could pressure valuation absent clear clinical or commercialization progress. EPS Estimates

Aktis Oncology Trading Up 2.3%

Shares of AKTS stock opened at $19.41 on Monday. The firm’s fifty day simple moving average is $19.76. Aktis Oncology has a 1 year low of $16.80 and a 1 year high of $29.16.

Insider Transactions at Aktis Oncology

In other Aktis Oncology news, major shareholder Ansbert Gadicke acquired 1,112,777 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the transaction, the insider owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This represents a 12.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of Aktis Oncology stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the transaction, the insider owned 10,260,064 shares of the company’s stock, valued at $184,681,152. This represents a 12.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 6,117,776 shares of company stock worth $110,119,968. 3.30% of the stock is owned by corporate insiders.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.